Detection of multiple PRL- and GH-like proteins in human pituitary by Western blot analysis.

Surgically removed normal and tumorous pituitary tissues from a prolactinoma patient were analyzed by Western blot techniques for PRL and GH variants. Criteria for identification were the Rf of the bands within the gel, immunologic crossreactivity to specific antisera, and structural verification by tyrosine peptide-mapping of individual bands from the gel. The authors found the tumor-tissue to be characterized by the presence of a PRL band greater in concentration than in the normal tissue and the virtual absence of a GH band. Immunoblotting of the electrophoretically resolved proteins form both types of tissues revealed several new bands crossreactive with human PRL and GH antibodies. Some of the new bands were of Mr greater than the monomeric PRL and GH and others were of lower Mr. Relative of two of the low mobility Mr PRL-immunoreactive bands designated as 16K and 8K corresponded to the Rf of the two fragments of cleaved PRL, which suggested that cleaved PRL occurred naturally in the human pituitary gland. The most conspicuous of the new PRL-immunoreactive bands, a 25,000 Mr protein migrating slightly behind PRL, displayed strong crossreactivity to hPRL antibodies and was present in greater concentration in the prolactinoma tissue than in the normal tissue. These properties suggested that it was related to hPRL and perhaps represented its glycosylated variant. However, its tyrosine peptide map did not resemble that of hPRL. Thus, it is not clear whether it represented G-hPRL or a new pituitary protein that cross-reacts with hPRL antibodies. In addition, two other bands of low Mr, designated as unknown 1 and unknown 2, reacted with hPRL antibodies. Immunostaining with hGH antibodies revealed the 20K-hGH variant, the F1 fragment of cleaved hGH, and a pair of new bands immediately behind GH that could represent glycosylated hGH--possibly a product of Seeburg's variant hGH gene. Both PRL and GH antibodies elicited numerous bands of high Mr by the technique employed, far more than ever observed by Sephadex chromatography. The nature of the high Mr bands remains unknown. Further characterization of these new PRL- and GH-immunoreactive proteins might help in the understanding of the multiple physiologic functions of PRL and GH in man.

Demonstration of 20K growth hormone in human plasma by gel electrophoretic-immunostaining-autoradiographic assay (GEISAA).

A variant of human growth hormone (hGH), in which 15 amino acids are missing (commonly referred to as 20K-hGH in contrast to the traditional form which is referred to as 22K-hGH), is known to exist in human pituitary glands. However, lack of a method to measure it in blood has hindered investigations of its physiopathology. We have applied a newly-developed technique called GEISAA for its detection in small volumes of human plasma. The method is based upon the lower Mr of the variant and its ability to partially crossreact with existing antibodies for 22K-hGH. It consists of retrieval of the substance from plasma by immunoprecipitation, separation from 22K-hGH by NaDodSO4-polyacrylamide gel electrophoresis, transfer onto nitrocellulose paper by electroblotting and visualization by immunostaining and autoradiography. It revealed the 20K-hGH in plasma of some normal individuals and in that of an acromegalic patient. Furthermore, plasma concentration of the variant rose in conjunction with 22K-hGH following exercise, a natural stimulus for GH release. These results show that the 20K-hGH circulates under normal conditions and it is measurable by GEISAA using existing antibodies.

Glycosylated human prolactin.

A glycosylated form of human PRL (G-hPRL) was isolated from pituitary glands. The glycoprotein was separated from the major form of PRL on columns of lentil lectin-Sepharose 4B. The major form of PRL did not bind to the lentil lectin, whereas the glycosylated modification did and could be eluted with methyl-alpha-D-mannopyranoside. By gel electrophoresis in sodium dodecyl sulfate, a mol wt of 25,000 was estimated for the glycosylated PRL. The mol wt of hPRL is 23,000. In a RIA for hPRL, the glycosylated hormone was about one third as reactive as the principal form. Since there is only one Asn-X-Ser(Thr) sequence in hPRL, the asparagine at position 31 is the likely point of N-linked glycosylation.

Antigenic sites of human growth hormone and related molecules detected by monoclonal antibodies to human growth hormone.

Four major antigenic sites for human growth hormone (hGH) were identified by 27 mouse monoclonal antibodies to hGH. Sites 1 and 2 are spatially close whereas sites 3 and 4 are located in other parts of the molecule. There also appears to be a subdivision of antigenic sites. A panel of 10 monoclonal antibodies, which included representatives from each antigenic site group, were used to determine cross-reactivities between hGH and human placental lactogen (hPL), human prolactin (hPRL), the 20,000 mol. wt variant of hGH (hGH20K) and a disulfide-linked dimer of hGH (diS-dimer). The data suggest a high conformational dependence of antigenic sites in hGH. DiS-dimer retains all four antigenic sites of hGH, although all have been altered. hGH20K retains sites 2-4 but site 1 has been dramatically altered. hPL retains site 3, whereas sites 1 and 4 have been dramatically altered and site 2 may be lacking. The extremely low cross-reactivity observed for hPRL is consistent with the dissimilarity between hGH and hPRL. Antigenic site 3 is the most conserved of all sites. The lack of structural similarity compared with hGH of site 1 in hGH20K and of a portion of site 3 in diS-dimer suggests that it may be possible to develop specific radioimmunoassays for these structural variants of hGH.

Radioimmunoassay of human prolactin based on a 13 amino acid synthetic analog of the amino terminus.

A 13 amino acid analog of the human prolactin amino terminus was synthesized, substituting tyrosine for valine at residue 13. The peptide was coupled to crystalline bovine serum albumin for antisera production. The peptide was used for iodination with 125I, and displacement curves were found to be parallel when human prolactin and the synthetic peptide were compared as standards. The radioimmunoassay using the synthetic peptide has the advantages of purity in its roles as hapten in the antigen and as labelled peptide, of ease of iodination of the peptide, of its stability after iodination, and of obviating the need for native human prolactin. The radioimmunoassay is suitable for the measurement of human prolactin concentration in plasma.

Production of antibodies by inoculation into lymph nodes.

The intra-lymph node technique used to inoculate rabbits with small quantities of antigen has been described. A variety of antigens in the 20,000-22,000 molecular weight range, as well as a 15-amino acid peptide coupled to BSA, have been inoculated successfully by this procedure. We have made no attempt to compare the success rate of the intra-lymph node inoculation route with other techniques utilizing small (microgram) quantities of antigen.

Effect on growth of prolactin deficiency induced in infant mice.

The effect of lowering PRL levels in blood during early infancy on subsequent growth and development was studied in mice. PRL was reduced by injecting either an antiserum raised against homologous PRL or a PRL-inhibiting drug, 2-chloro-6-methylergoline-8 beta-acetonitrile methanesulfonate (ergoline), into 4-day-old mice for a period of 4 or 5 days. Both the anti-PRL serum and ergoline rapidly killed some of the injected animals, but the effect of anti-PRL serum was much more severe than that of ergoline (39% vs. 8.7% mortality during the period of injection). Similar administration of an antiserum against mouse GH or the GH-inhibiting peptide somatostatin did not cause a significant number of deaths. The deaths from the anti-PRL serum largely ceased when the antiserum was neutralized with rat PRL (NIH-RP-1) before injection. The gain in body weight of baby mice was markedly retarded within 24 h of injecting anti-PRL serum and ergoline, in contrast to the anti-GH serum and somatostatin injections, which took 3--4 days to inhibit growth perceptibly. The anti-PRL serum, despite having only one eighth the titer of anti-GH serum, was by far the most effective of the two antisera in diminishing tibial epiphyseal cartilage width as well as weights of pituitary glands, testes, and adrenals and retarding sexual maturity. The more severe and generalized developmental abnormalities and the incidence of mortality as a result of anti-PRL serum administration suggest that PRL in mice may be involved in the maintenance of some vital function during infancy.

The biological half-life of human growth hormone and a biologically active 20,000-dalton variant in mouse blood.

We compared the disappearance rate of hGH and hGH20K injected into groups of mice. Radioactivity measurements and RIA were used to determine the amount of hormone in blood collected at various times after injection. The results indicate that the T1/2 value for hGH and hGH20K are equal. We conclude that there is no apparent relationship between the equal rates of disappearance, the dissimilar binding characteristics that have been shown for the hormones and their equipotent growth promoting activities.

Binding characteristics of a biologically active variant of human growth hormone (20K) to growth hormone and lactogen receptors.

The dose-dependent displacement characteristics of a biologically active 20,000 molecular weight human pituitary growth hormone variant (20K) and of human growth hormone (hGH) were compared using hGH liver plasma membrane receptors both from 20-30 day pregnant rabbits and from normal female rats and also using mammary gland plasma membrane receptors from 5-6 day lactating rabbits. Different preparations of 20K were found to be only 3-20% as potent as hGH when compared at the dose necessary to cause 50% displacement of (125I)iodo-hGH from liver receptor and was 22-53% as effective as hGH in the mammary receptor assay system. These findings suggest that 20K and hGH may have separate receptors or that the binding characteristics of the two hormones may be quite different.

Effects of calcium, lanthanum, and temperature on the fluidity of spin-labeled human platelets.

Previous platelet studies have shown that calcium plays important roles in stimulus-secretion coupling, aggregation, and other membrane-associated functions. In addition, lanthanum induces platelet aggregation and the platelet release reaction and also influences platelet responsiveness to various stimuli. The spin-label results presented here suggest that one mechanism through which calcium and lanthanum mediate their effects on platelet functions may be by decreasing the lipid fluidity of the surface membrane. The structure of platelet membrane lipids was examined with the spin-label method. Washed human platelets were labeled with the 5-, 12- and 16-nitroxide stearic acid spin probes. Order parameters which measure the fluidity of the lipid environment of the incorporated probe may be calculated from the electron spin resonance (ESR) spectra of 5-nitroxide stearate [I(12,3)]-labeled cells. Evidence is presented which indicates that these spectra principally reflect properties of the platelet surface membrane lipids. The membrane fluidity increased with temperature for the range 17 to 37 degrees C. Either calcium or lanthanum additions to intact cells increased the rigidity of the platelet membranes at 37 degrees C, although the La3+ effect was larger and occurred at lower concentrations than that of Ca2+. For example, addition of 1 mM La3+ or 4 mM Ca2+ increased the order parameter of I(12,3)-labeled platelets by 4.3 +/- 1.7% or 2.1 +/- 0.5%. Preliminary studies conducted on purified platelet plasma membranes labeled with I(12,3) indicated that 1 mM LaCl3 or 4 mM CaCl2 additions similarly decreased the lipid fluidity at 37 degrees C. The above cation-induced effects on the fluidity of whole platelets were reversed by the use of the divalent cation-chelating agent ethylene glycol-bis-(beta-aminoethyl ether)-N,N'-tetra-acetic acid (EGTA). Lastly, lanthanum (0.2-1 mM) caused rapid aggregation of platelets which were suspended in a 50-mM Tris buffer pH 7.4 that did not contain adenosine.

Serum, pituitary and urine concentrations of prolactin and growth hormone in eight strains of mice with varying incidence of mammary tumors.

Eight inbred strains of mice with varying incidences of spontaneous mammary tumor were compared in regard to prolactin and growth hormone concentrations in sera, pituitary glands and urine. Serum prolactin was compared under basal conditions as well as after stimulation with perphenazine. Both hormones were measured with specific, homologous radioimmunoassays. Although some strains having a high incidence of mammary tumors had high levels of prolactin in sera, urine and pituitary glands, neither basal nor perphenazine-induced serum concentrations showed a consistent pattern across mouse strains that correlated with the incidence of mammary tumors. Growth hormone levels in sera, pituitary glands and urine also had no characteristic pattern that applied to all strains studied. The ratio of prolactin depleted from the pituitary gland to prolactin detected in serum after perphenazine injection, which reflected the metabolic clearance rate of prolactin, was highest in two strains with a high incidence of mammary tumors and relatively lower in low-tumor strains. These results suggest that if prolactin plays a part in mammary tumor development in mice, its mechanism varies with strains: while hyperprolactinemia may be the means in some strains, a peculiarity in the metabolism of the hormone may be more important in others.